Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e
Pfizer reaped the rewards of its COVID-19 vaccines and therapeutics in 2022, but there are already signs of falling demand that looks likely to get significantly worse in
Pfizer's decision to raise the price of its COVID-19 vaccine next year has prompted a rebuke from two Democrat senators in the US, who have accused the company of "unseemly profiteering."
A submission to the US Food and Drug Administration (FDA) requesting an Emergency Use Authorization (EUA) of a 10-µg booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for
Pfizer and BioNTech's COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA's human medicines committee, shortly after the panel gave its blessi
Eleven new digital health start-ups have graduated from PharmStars’ twice-yearly education and mentoring programme, with the latest crop focusing on digital innovations in
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio